Trial Profile
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Glufosfamide (Primary) ; Fluorouracil
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eleison Pharmaceuticals
- 11 Oct 2023 Planned End Date changed from 1 Mar 2023 to 1 Dec 2025.
- 11 Oct 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2025.
- 06 May 2021 Planned End Date changed from 1 Jun 2021 to 1 Mar 2023.